| 1. |
WHO Scientific Group on the Prevention and Management of Osteoporosis. Prevention and management of osteoporosis[R]. Geneva: World Health Organization, 2003: 2-3.
|
| 2. |
中国健康促进基金会骨质疏松防治中国白皮书编委会. 骨质疏松症中国白皮书[J]. 中华健康管理学杂志, 2010, 3(3): 148-154.
|
| 3. |
Russell RG. Bisphosphonates: the first 40 year[J]. Bone, 2011, 49(1): 2-19.
|
| 4. |
Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy[J]. Osteoporos Int, 2008, 19(6): 733-759.
|
| 5. |
Rodan G, Reszka A, Golub E, et al. Bone safety of long-term bisphosphonate treatment[J]. Curr Med Res Opin, 2004, 20(8): 1291-1300.
|
| 6. |
Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management[J]. Mayo Clin Proc, 2009, 84(7): 632-638.
|
| 7. |
Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy[J]. J Clin Endocrinol Metab, 2005, 90(3): 1294-1301.
|
| 8. |
Eastell R, Walsh JS, Watts NB, et al. Bisphosphonates for postmenopausal osteoporosis[J]. Bone, 2011, 49(1): 82-88.
|
| 9. |
Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis[J]. J Clin Endocrinal Metab, 2010, 95(4): 1555-1565.
|
| 10. |
Briot K, Tremollieres F, Thomas T, et al. How long should patients take medications for postmenopausal osteoporosis[J]. Joint Bone Spine, 2007, 74(1): 24-31.
|
| 11. |
Ott SM. What is the optimal duration of bisphosphonate therapy?[J] Cleve Clin J Med, 2011, 78(9): 619-630.
|
| 12. |
Cummings SR, Black DM, Thompson DE, et al. Effects of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial[J]. JAMA, 1998, 280(24): 2077-2082.
|
| 13. |
Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group[J]. Lancet, 1996, 348(9041): 1535-1541.
|
| 14. |
Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial[J]. JAMA, 2006, 296(24): 2927-2938.
|
| 15. |
Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women[J]. N Engl J Med, 2004, 350(12): 1189-1199.
|
| 16. |
Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women[J]. J Clin Endocrinol Metab, 2000, 85(9): 3109-3115.
|
| 17. |
Ravn P, Weiss SR, Rodriguez-Portales JA, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group[J]. J Clin Endocrinol Metab, 2000, 85(4): 1492-1497.
|
| 18. |
Wasnich RD, Bagger YZ, Hosking DJ, et al. Changes in bone density and turnover after alendronate or estrogen withdrawal[J]. Menopause, 2004, 11(6 Pt 1): 622-630.
|
| 19. |
Michalska D, Stepan JJ, Basson BR, et al. The effects of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis[J]. J Clin Endocrinol Metab, 2006, 91(3): 870-877.
|
| 20. |
Mille PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate[J]. J Clin Endocrinol Metab. 2008, 93(10): 3785-3793.
|
| 21. |
Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis[J]. J Clin Endocrinol Metab, 2008, 93(3): 852-860.
|
| 22. |
Curtis JR, Westfall AO, Cheng H, et al. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday[J]. Osteoporos Int, 2008, 19(11): 1613-1620.
|
1/5
WeChat